Spanish Series of Patients Treated With the Radionuclide Lutetium177

Launched by SOCIEDAD ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR · Jul 1, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a treatment called Lutetium-177-DOTATATE, which is used for patients with certain types of tumors, including neuroendocrine tumors and other related cancers. The goal is to gather information from various hospitals in Spain about how effective and safe this treatment is when it is given as part of regular care. Researchers want to learn more about the different kinds of patients and tumors being treated, as well as the outcomes for each group.

To participate in this trial, patients must be at least 18 years old and have a specific type of tumor that cannot be removed by surgery or has spread to other parts of the body. Patients will need to give their permission before joining the study. There are no specific exclusion criteria, meaning most patients with the right diagnosis are welcome to participate. Those who take part can expect to receive this treatment and contribute to important research that could help improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent must be obtained prior to any data collection.
• • Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
• • Aged ≥18 years.
• Exclusion Criteria:
• • None